ABSTRACT
roduction: The recent prevalence of dermatophytosis in India ranges from 36.6 to 78.4%. Itraconazole is commonly usedsystemic antifungal to treat dermatophytosis.Objective: The objective of the present study was to evaluate the effectiveness and safety of itraconazole given 100 mg twicedaily for the treatment of dermatophytosis.Materials and Methods: The present retrospective questionnaire-based survey was done, wherein dermatologists and generalphysicians were given survey questionnaire. Data analysis up to 4 weeks of treatment with itraconazole was considered forthis study. Efficacy evaluation was considered as percentage of patients achieving clinical cure.Results: A total of 150 doctors completed the survey involving 1100 patients. Out of 1100 patients, 341 patients (31%)responded well to topical therapy alone and were considered as clinically cured as per medical records. In remaining patientswho did not respond well to topical monotherapy, itraconazole was found to be added in 652 patients as 100 mg twice daily for4 weeks. Of these, 456 patients (70%) responded well to therapy in 4 weeks and were considered as clinically cured. Amongthe topical antifungals coprescribed with itraconazole, luliconazole was most commonly prescribed (49%). On comparison ofclinical cure rates in patients who received topical antifungal monotherapy (31%) and itraconazole cotherapy (70%), it was foundthat itraconazole cotherapy was better and the difference between the two therapies was statistically significant (P = 0.001).Conclusion: From the findings of the present analysis, clinical cure rates obtained with itraconazole were more than satisfactory.Although the standard duration of therapy ranges from 1 to 2 weeks, long-term treatment is warranted and that is with topicalantifungals and other supportive measures.
ABSTRACT
After hemorrhage, anemia is the most common cause of maternal mortality and leading cause of maternal morbidity in India. Theprevalence rates of anemia in pregnancy in India is estimated to be >50%. Iron deficiency anemia (IDA) is the most commontype of anemia in pregnancy in India, which I can be as high as 80–90%.Aims and Objectives: The present survey was initiated in pursuit of analyzing the effectiveness and safety of oral ferricpyrophosphate (FPP) formulation given once to twice daily for treatment and prophylaxis of IDA in pregnancy.Materials and Methods: This was a questionnaire-based retrospective survey. Each gynecologist was given this survey bookletcontaining questionnaire. Clinical response was assessed by measuring rise in mean hemoglobin (Hb) levels at baseline, week4, and week 8, after giving oral FPP formulation for 8 weeks.Results: A total of 60 gynecologists participated and completed the survey, which involved 1073 pregnant subjects and patientssuffering from IDA (864 patients, i.e., 80%). Mean Hb level at baseline was found to be 8.98 g/dl, 10.03 at week 4, and 10.99 atweek 8. Thus, rise of Hb from baseline to week 8 was found to be 2.01 g/dl. Adverse events were reported in only 10 patients(<0.09%), none requiring discontinuation of therapy. 98% of the participants agreed good acceptability of oral FPP formulation.Conclusion: Findings of the present survey suggests that oral FPP formulation therapy can serve as potent choice of therapyfor IDA in pregnancy, both therapeutically and prophylactically